While chimeric antigen receptor (CAR) T cell-based therapy has been approved for clinical use for certain types of blood cancers, it remains difficult to achieve precise spatiotemporal control of the elicited anti-tumour response. Here, the authors propose light-switchable CAR T cells that can be remotely activated by a nano-optogenetic approach, reducing unwanted side effects.
- Nhung Thi Nguyen
- Kai Huang
- Yubin Zhou
